Document Detail

Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease.
MedLine Citation:
PMID:  17924559     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: For a patient to make informed, preference based decisions, they must be able to balance the risks and benefits of treatment. The aim of this study was to determine patients' and parents' perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease (IBD). METHODS: Adult patients with IBD and parents of patients attending IBD patient education symposiums were asked to complete a questionnaire regarding the risks and benefits of infliximab. RESULTS: One hundred and sixty-five questionnaires were completed. A majority (59%) of respondents expected a remission rate greater than 50% at 1 year and 18% expected a remission rate greater than 70% at 1 year. More than one-third (37%) of respondents answered that infliximab is not associated with a risk of lymphoma and 67% responded that the lymphoma risk is no higher than twice that of the general population. When presented a scenario of a hypothetical new drug for IBD with risks mirroring those estimated for infliximab, 64% of respondents indicated that they would not take the medication, despite its described benefits. Thirty percent of these patients were either currently taking or had previously taken infliximab. Patients actively taking infliximab predicted the highest remission rates for the infliximab (P = 0.05), and parents of patients predicted the lowest (P = 0.01). Parents estimated a higher risk of lymphoma than patients (P = 0.003). Risk and benefit perception was independent of gender and age of patient respondents. CONCLUSIONS: Compared to published literature, patients and parents of patients overestimate the benefit of infliximab and underestimate its risks. We conclude that effective methods for communicating risks and benefits to patients need to be developed.
Corey A Siegel; L Campbell Levy; Todd A Mackenzie; Bruce E Sands
Related Documents :
16741249 - Immunoglobulin free light chains and solitary plasmacytoma of bone.
24228889 - Section 3. a discussion of flexible dosing and patient-centered therapy: highlights of ...
24015339 - A multicenter, retrospective study of patients with pulmonary arterial hypertension tra...
14671469 - The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.
8919599 - Cholesterol screening in a community pharmacy.
10492489 - Study of cardiovascular risk intervention by pharmacists (scrip): a randomized trial de...
21107529 - Use of early corticosteroid therapy on icu admission in patients affected by severe pan...
18473099 - Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outco...
1157269 - Refractory periods of the accessory pathway in the wolff-parkinson-white syndrome.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Inflammatory bowel diseases     Volume:  14     ISSN:  1078-0998     ISO Abbreviation:  Inflamm. Bowel Dis.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-17     Completed Date:  2008-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508162     Medline TA:  Inflamm Bowel Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-6     Citation Subset:  IM    
Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Health Knowledge, Attitudes, Practice*
Inflammatory Bowel Diseases / drug therapy*
Middle Aged
Patient Acceptance of Health Care / statistics & numerical data*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, ...
Next Document:  Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids.